Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915292 | 1.00 | BLM (0.39) | BLMRARBGPR84FFAR1KDM4C | |
| SCHEMBL31396834 | 1.00 | BLM (0.39) | BLMRARBGPR84FFAR1KDM4C | |
| SCHEMBL5471739 | 0.93 | RARB (0.39) | BLMRARBKDM4CTSHRKDM4A | |
| SCHEMBL3285954 | 0.93 | RARB (0.39) | BLMRARBKDM4CTSHRKDM4A | |
| SCHEMBL11330559 | 0.87 | TSHR (0.48) | BLMTSHRNOD1CHRM2CHRM4 | |
| SCHEMBL28001738 | 0.85 | TSHR (0.42) | BLMTSHR | |
| SCHEMBL28411335 | 0.84 | TSHR (0.50) | TSHRNOD1 | |
| Cadaverine Tartrate SCHEMBL27887855 | 0.82 | TSHR (0.58) | BLMRARBTSHR | |
| SCHEMBL41759 | 0.81 | NAAA (0.52) | GPR84FFAR1TSHRMAPTNOD1 | |
| SCHEMBL17986646 | 0.81 | NAAA (0.52) | GPR84FFAR1TSHRMAPTNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238746-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | FOAMIX PHARMACEUTICALS LTD (IL) | 2019-03-26 | — | — | US | claimed |
| US-20180193469-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | FOAMIX PHARMACEUTICALS LTD. (IL) | 2018-07-12 | — | — | US | claimed |
| US-8618081-B2 | Compositions, gels and foams with rheology modulators and uses thereof | FOAMIX LTD. (IL) | 2013-12-31 | — | — | US | claimed |
| WO-2024220589-A2 | USES OF PAN BET INHIBITORS CROSS-REFERENCE TO RELATED APPLICATIONS | VYNE THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240325393-A1 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | VYNE THERAPEUTICS INC. | 2024-10-03 | — | — | US | disclosed |
| US-20230037905-A1 | TOPICAL COMPOSITION COMPRISING TOFACITINIB AND FINGOLIMOD | VYNE THERAPEUTICS INC. | 2023-02-09 | — | — | US | disclosed |
| CN-114980957-A | Metered dose for intraocular or periocular disorders | 阿祖拉眼科有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114980895-A | Metered dose for demodex and related disorders | 阿祖拉眼科有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114469991-A | Selenium disulfide composition for treating meibomian gland dysfunction | 阿祖拉眼科有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-11324691-B2 | Compositions and methods for treating rosacea and acne | JOURNEY MEDICAL CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210205212-A1 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE | SWK FUNDING LLC | 2021-07-08 | — | — | US | disclosed |
| US-10849847-B2 | Compositions and methods for treating rosacea and acne | Foamix Pharamaceuticals Ltd. (IL) | 2020-12-01 | — | — | US | disclosed |
| US-10398641-B2 | Compositions and methods for treating rosacea and acne | FOAMIX PHARMACEUTICALS LTD. (IL) | 2019-09-03 | — | — | US | disclosed |
| US-10322186-B2 | Topical tetracycline compositions | FOAMIX PHARMACEUTICALS LTD. (IL) | 2019-06-18 | — | — | US | disclosed |
| US-10137200-B2 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | FOAMIX PHARMACEUTICALS LTD. (IL) | 2018-11-27 | — | — | US | disclosed |
| US-20180193469-A1 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | FOAMIX PHARMACEUTICALS LTD. (IL) | 2018-07-12 | — | — | US | disclosed |
| US-20180064638-A1 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE | FOAMIX PHARMACEUTICALS LTD. | 2018-03-08 | — | — | US | disclosed |
| US-20070275022-A1 | Cosmetic Hair Preparation | LION CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275022-A1 | Cosmetic Hair Preparation | CUTA, H1-10, PUF60 | BLM 885/4885RARB 495/4885GPR84 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.